Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
45,941,687
-
Share change
-
+1,437,310
-
Total reported value
-
$1,098,891,390
-
Put/Call ratio
-
60%
-
Price per share
-
$23.92
-
Number of holders
-
132
-
Value change
-
+$30,175,470
-
Number of buys
-
70
-
Number of sells
-
65
Institutional Holders of AIMMUNE THERAPEUTICS INC - COM (AIMT) as of Q4 2018
As of 31 Dec 2018,
AIMMUNE THERAPEUTICS INC - COM (AIMT) was held by
132 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
45,941,687 shares.
The largest 10 holders included
PRICE T ROWE ASSOCIATES INC /MD/, BlackRock Inc., Vanguard Group Inc, Foresite Capital Management II, LLC, FMR LLC, Aisling Capital LLC, ALLIANCEBERNSTEIN L.P., STATE STREET CORP, WELLINGTON MANAGEMENT GROUP LLP, and EVENTIDE ASSET MANAGEMENT, LLC.
This page lists
132
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.